KFF Health News, written up by Futurism, reports on users of research-grade BPC-157 who describe fatigue, spasms and migraines lasting months after a few days of use. A former FDA official quoted in the piece says robust human studies on these compounds remain rare.
NextWave Peptides has announced a U.S.-based research peptide catalog organized around a lot-matched COA library and a stated 99%+ purity standard. The announcement is a company press release, and it does not name the third-party lab or say how much of the catalog the documentation covers.
A sponsored explainer on Whig.com surveys proposed roles for Thymosin Alpha-1 in immune signaling, stress response and antigen presentation, then closes by pointing readers to a vendor. Every claim in the body is hedged, and no trial size or outcome figure appears anywhere in the piece.
A review in the Journal of Translational Medicine argues that the mitochondrial peptide MOTS-c acts as a context-dependent stress signal rather than a uniformly protective one. Human measurements remain inconsistent, and the cancer evidence points both ways.
AgelessRx has launched a prescription copper peptide cream in 0.5% and 3% strengths, compounded by licensed U.S. pharmacies and priced from $99 a month. The company reports 99.8% purity testing, but no clinical trial of the formulation is cited in the announcement.
GHK-Cu, the copper-binding tripeptide, has been studied for decades and sells for under $40 a vial, but the publicly available coverage is hedged mechanism talk, cell culture work and animal wound studies. A look at what three current sources actually claim, and what none of them establishes.
A sponsored explainer on GHK-Cu lays out theorized roles in gene expression, extracellular matrix biology and oxidative balance, all in hedged language. Its own citation list runs to fibroblast cultures, a veterinary wound study and three reviews by the same author.
A preprint survey of 829 GLP-1 receptor agonist users reports reduced alcohol use in 72 percent of drinkers and near-universal side effects that two-thirds said barely affected life satisfaction. It is self-reported, uncontrolled and self-selected, which is exactly how far the findings go.
Nox Peptides has launched GHK-Cu and a combination product containing BPC-157 and TB-500 for Canadian research buyers, the company said in an October 6 announcement. No trial, outcome figure or published study accompanies the launch, and the release makes no health claims.
A narrative review in Frontiers in Nutrition argues that protein and amino acid supplements are marketed on a single-active-ingredient model that does not match how metabolism behaves. The authors say mechanistic evidence for these products often exceeds the available clinical data, while flagging older adults and hypercatabolic states as genuine exceptions.
A paid advertorial published through Newswire examines Synthesis Peptides' advertised GHK-Cu price of $36.99, its volume tiers, and one linked Certificate of Analysis reporting 99.678% batch-average purity. The review says it did not authenticate that certificate with the issuing laboratory and reaches no verdict on the supplier.
Khloe Kardashian has praised Omi Women's Hair Growth Peptides on the record, calling the supplement the best thing that has happened to her hair. The formula's headline ingredient is a patented keratin-derived peptide complex, and every claim about it currently comes from the brand rather than a published trial.
A mechanistic review in Clinical and Experimental Allergy argues that GLP-1 receptor agonists may suppress Type 2 allergic inflammation directly, independently of weight loss. The authors say prospective human trials using Type 2 biomarkers are still needed to confirm the cellular mechanisms.
In a Women's Health essay, creator Nabela Noor describes escalating from oral diabetes medication to a GLP-1 after her second pregnancy, alongside Pilates and weight training, and says she has lost more than 60 pounds. She never names the drug, and the piece cites no trial data.
A JACC: Case Reports paper describes an 82-year-old heart failure patient whose mean pulmonary artery pressure fell 10 mm Hg after semaglutide was added to device-guided management. It is a single case with no control group, and the authors call for larger studies.
A new study in Childhood Obesity reports that 16.8% of patients ages 10 to 17 were diagnosed with a nutritional deficiency within a year of starting a GLP-1 medication, with vitamin D deficiency most common at 12.4%. Only 5% received nutritional counseling in the first 30 days.
A Frontiers in Nutrition review places declining NAD+ metabolism at the center of brain aging, linking vitamin B3 precursors, exercise and gut microbiota through shared signaling pathways. The authors note most supporting evidence is preclinical and say clinical relevance in neurodegenerative disease is not yet established.
A cross-sectional study of 79 adults with obesity found higher sweet taste detection thresholds in GLP-1 receptor agonist users, while most other chemosensory measures were unchanged. Six-month users also reported lower food noise, cravings and energy intake, though the design cannot establish cause.
Jennifer Aniston told The Wall Street Journal in 2023 that weekly peptide injections were the future of skincare, but dermatologists quoted by Grazia say the injectable market still lacks human safety trials. The FDA has warned against these products, and the AMA says the evidence is not there to recommend them.
Hi-Tech Pharmaceuticals says it has launched PRO IGF-1 nationwide, a whey-derived IGF-1 peptide supplement it claims is the first of its kind. The announcement carries two company figures and no published trial data.
Umbrella Labs says it has standardized naming, identity fields, and batch traceability for its MOTS-C research material, with no biological claims attached. The announcement is a procurement story rather than a science one, and the company says the material's research-use-only scope is unchanged.
Ritual's CEO told Glossy the brand is entering perimenopause care with two products, a Giant Spoon campaign, and its first celebrity spokesperson, to be named October 1. The $39-per-month formula lists shatavari, DIM, vitamin B6 and evening primrose oil, and a clinical trial for it is still only a proposal.
A 45-member expert panel in World Psychiatry reached 91.7% average consensus on recommendations for GLP-1 receptor agonist use in people with eating disorders, including pre-prescription screening. The panel says the drugs should generally be avoided in active anorexia nervosa and restrictive bulimia nervosa, and that trials in binge eating disorder are still missing.
Recent collagen peptide research spans frozen dough stabilization and cell-culture hydrogel scaffolds, alongside a new consumer gummy launch. None of it reports a human clinical outcome, which is worth knowing before reading the marketing.
A cohort study of 342,932 treatment initiations found GLP-1 receptor agonist starts rose from 1,988 to 44,852 a year among U.S. adults with type 2 diabetes and obesity, while bariatric surgery stayed rare. Around half of initiators were adherent, and roughly half were off their initial treatment within a year.
A paid advertorial promoting the NEOLISE Longevity protocol discloses that neither CJC-1295 nor ipamorelin is FDA-approved and that an FDA advisory committee voted against both as bulk compounding substances. It also notes the brand does not name its prescribing provider group or compounding pharmacy.
A Nature Communications study found that participants taking weekly semaglutide showed slowed epigenetic aging markers across blood, brain, heart, liver, and kidney cells over 32 weeks. The trial was small and limited to adults with HIV-associated lipohypertrophy, and the lead author says the work does not show aging being reversed.
Synthesis Peptides says it now pulls eight vials at random from every production lot for HPLC and LC-MS testing, with batch-specific Certificates of Analysis published publicly. The release names no purity threshold and does not identify the independent testing lab.
A Quebec court has granted Health Canada a permanent injunction against a company selling unauthorized injectable peptides, as researchers describe a consumer market moving faster than regulation. Popular online compounds including BPC-157 and KPV have little or no human evidence behind them.
Three recent reports touch semaglutide from different angles: an unexpected brain mechanism in mice, a combination experiment with an experimental fat-burning compound, and laboratory redesign of the peptide's structure. None of the three involved human participants.
